Panobinostat 10mg capsules
Requires a prescription from a doctor or prescriber
Panobinostat is an oral deacetylace (DAC) inhibitor approved on February 23, 2015 by the FDA for the treatment of multiple myeloma.
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Suspected adverse reactions reported for Panobinostat
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
View EudraVigilance report
Suspected adverse reactions reported for Panobinostat
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
1 branded products available
MHRA licensed products
View all licensed products for Panobinostat on the MHRA register
Farydak 10mg capsules
Therapeutically similar medicines
Similarity based on WHO Anatomical Therapeutic Chemical (ATC) classification and NHS BNF section grouping. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Clinical guidelines and formulary information
British National Formulary
Panobinostat
Source: British National Formulary, NICE. Joint Formulary Committee. Contains public sector information licensed under the Open Government Licence v3.0.
NICE clinical guidance(14)
Panobinostat for treating multiple myeloma after at least 2 previous treatments (TA380)
Pomalidomide for multiple myeloma previously treated with lenalidomide and bortezomib (TA427)
Selinexor with bortezomib and dexamethasone for previously treated multiple myeloma (TA974)
Daratumumab monotherapy for treating relapsed and refractory multiple myeloma (TA783)
Teclistamab for treating relapsed and refractory multiple myeloma after 3 or more treatments (TA1015)
Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma (TA658)
Selinexor with dexamethasone for treating relapsed and refractory multiple myeloma after 4 or more treatments (TA970)
Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (TA870)
Daratumumab in combination for untreated multiple myeloma when a stem cell transplant is suitable (TA763)
Lenalidomide plus dexamethasone for previously untreated multiple myeloma (TA587)
Elranatamab for treating relapsed and refractory multiple myeloma after 3 or more treatments (TA1023)
Carfilzomib with dexamethasone and lenalidomide for previously treated multiple myeloma (TA695)
Lenalidomide plus dexamethasone for multiple myeloma after 1 treatment with bortezomib (TA586)
Belantamab mafodotin with pomalidomide and dexamethasone for previously treated multiple myeloma (TA1133)
Source: National Institute for Health and Care Excellence (NICE). Contains public sector information licensed under the Open Government Licence v3.0.
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & product information
Official product databases and supply status monitoring
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. emc (electronic medicines compendium) is operated by Datapharm Ltd. Shortage information sourced from NHS Specialist Pharmacy Service (SPS), sps.nhs.uk.
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF codes from NHS Business Services Authority (NHSBSA). ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Approved
Major interactions
None known
Half-life
30 hours
Mechanism
Panobinostat is a deacetylase (DAC) inhibitor.
Food interactions
5 warnings
Human targets
2 targets
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Absorption
20 mg
Half-life
30 hours
Metabolism
2%
Pharmacokinetic data: DrugBank · CC BY-NC 4.0
Known interactions with other medications. Always consult a healthcare professional.
Showing 50 of 1252 interactions
How the body processes this drug — absorption, distribution, metabolism, and elimination
CYP and non-CYP enzymes were found to play significant role in metabolism, CYP2D6 and CYP2C19 playing minor roles.
Proteins and enzymes this drug interacts with in the body
PMID:12024216 PMID:18606987 PMID:20308065 PMID:24882211 PMID:26246421 PMID:30538141 PMID:31857589 PMID:30770470 PMID:38534334 PMID:39567688
Plays a central role in microtubule-dependent cell motility by mediating deacetylation of tubulin .
PMID:12024216 PMID:20308065 PMID:26246421
Required for cilia disassembly via deacetylation of alpha-tubulin .
PMID:17604723 PMID:26246421
Alpha-tubulin deacetylation results in destabilization of dynamic microtubules (By similarity). Promotes deacetylation of CTTN, leading to actin polymerization, promotion of autophagosome-lysosome fusion and completion of autophagy .
PMID:30538141
Deacetylates SQSTM1 .
PMID:31857589
Deacetylates peroxiredoxins PRDX1 and PRDX2, decreasing their reducing activity .
PMID:18606987
Deacetylates antiviral protein RIGI in the presence of viral mRNAs which is required for viral RNA detection by RIGI (By similarity). Sequentially deacetylates and polyubiquitinates DNA mismatch repair protein MSH2 which leads to MSH2 degradation, reducing cellular sensitivity to DNA-damaging agents and decreasing cellular DNA mismatch repair activities .
PMID:24882211
Deacetylates DNA mismatch repair protein MLH1 which prevents recruitment of the MutL alpha complex (formed by the MLH1-PMS2 heterodimer) to the MutS alpha complex (formed by the MSH2-MSH6 heterodimer), leading to tolerance of DNA damage .
PMID:30770470
Deacetylates RHOT1/MIRO1 which blocks mitochondrial transport and mediates axon growth inhibition (By similarity).
Deacetylates transcription factor SP1 which leads to increased expression of ENG, positively regulating angiogenesis .
PMID:38534334
Deacetylates KHDRBS1/SAM68 which regulates alternative splicing by inhibiting the inclusion of CD44 alternate exons .
PMID:26080397
Acts as a valine sensor by binding to valine through the primate-specific SE14 repeat region .
PMID:39567688
In valine deprivation conditions, translocates from the cytoplasm to the nucleus where it deacetylates TET2 which promotes TET2-dependent DNA demethylation, leading to DNA damage .
PMID:39567688
Promotes odontoblast differentiation following IPO7-mediated nuclear import and subsequent repression of RUNX2 expression (By similarity). In addition to its protein deacetylase activity, plays a key role in the degradation of misfolded proteins: when misfolded proteins are too abundant to be degraded by the chaperone refolding system and the ubiquitin-proteasome, mediates the transport of misfolded proteins to a cytoplasmic juxtanuclear structure called aggresome .
PMID:17846173
Probably acts as an adapter that recognizes polyubiquitinated misfolded proteins and targets them to the aggresome, facilitating their clearance by autophagy .
PMID:17846173
Involved in the MTA1-mediated epigenetic regulation of ESR1 expression in breast cancer PMID:24413532
PMID:16762839 PMID:17704056 PMID:28497810
Histone deacetylation gives a tag for epigenetic repression and plays an important role in transcriptional regulation, cell cycle progression and developmental events .
PMID:16762839 PMID:17704056
Histone deacetylases act via the formation of large multiprotein complexes .
PMID:16762839 PMID:17704056
Acts as a component of the histone deacetylase NuRD complex which participates in the remodeling of chromatin .
PMID:16428440 PMID:28977666
As part of the SIN3B complex is recruited downstream of the constitutively active genes transcriptional start sites through interaction with histones and mitigates histone acetylation and RNA polymerase II progression within transcribed regions contributing to the regulation of transcription .
PMID:21041482
Also functions as a deacetylase for non-histone targets, such as NR1D2, RELA, SP1, SP3, STAT3 and TSHZ3 .
PMID:12837748 PMID:16285960 PMID:16478997 PMID:17996965 PMID:19343227
Deacetylates SP proteins, SP1 and SP3, and regulates their function .
PMID:12837748 PMID:16478997
Component of the BRG1-RB1-HDAC1 complex, which negatively regulates the CREST-mediated transcription in resting neurons .
PMID:19081374
Upon calcium stimulation, HDAC1 is released from the complex and CREBBP is recruited, which facilitates transcriptional activation .
PMID:19081374
Deacetylates TSHZ3 and regulates its transcriptional repressor activity .
PMID:19343227
Deacetylates 'Lys-310' in RELA and thereby inhibits the transcriptional activity of NF-kappa-B .
PMID:17000776
Deacetylates NR1D2 and abrogates the effect of KAT5-mediated relieving of NR1D2 transcription repression activity .
PMID:17996965
Component of a RCOR/GFI/KDM1A/HDAC complex that suppresses, via histone deacetylase (HDAC) recruitment, a number of genes implicated in multilineage blood cell development (By similarity). Involved in CIART-mediated transcriptional repression of the circadian transcriptional activator: CLOCK-BMAL1 heterodimer (By similarity). Required for the transcriptional repression of circadian target genes, such as PER1, mediated by the large PER complex or CRY1 through histone deacetylation (By similarity).
In addition to protein deacetylase activity, also has protein-lysine deacylase activity: acts as a protein decrotonylase and delactylase by mediating decrotonylation ((2E)-butenoyl) and delactylation (lactoyl) of histones, respectively PMID:28497810 PMID:35044827
Enzymes involved in drug metabolism — important for understanding drug interactions
Proteins that transport this drug across cell membranes
PMID:2897240 PMID:35970996 PMID:8898203 PMID:9038218 PMID:35507548
Catalyzes the flop of phospholipids from the cytoplasmic to the exoplasmic leaflet of the apical membrane. Participates mainly to the flop of phosphatidylcholine, phosphatidylethanolamine, beta-D-glucosylceramides and sphingomyelins .
PMID:8898203
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells PMID:2897240 PMID:35970996 PMID:9038218
ATC L01XH03
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Linked compound data from DrugBank Open Data (CC BY-NC 4.0)
Panobinostat
Additional database identifiers
ChemSpider
5294028
BindingDB
29589
PDB
LBH
ZINC
ZINC000022010649
HUGO Gene Nomenclature Committee (HGNC)
HGNC:4852
GenAtlas
HDAC1
GeneCards
HDAC1
GenBank Gene Database
U50079
GenBank Protein Database
1277084
Guide to Pharmacology
2658
UniProt Accession
HDAC1_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:19086
GeneCards
HDAC11
Guide to Pharmacology
2615
UniProt Accession
HDA11_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:4853
GenAtlas
HDAC2
GeneCards
HDAC2
GenBank Gene Database
U31814
GenBank Protein Database
1667394
Guide to Pharmacology
2616
UniProt Accession
HDAC2_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:4854
GenAtlas
HDAC3
GeneCards
HDAC3
GenBank Gene Database
U66914
GenBank Protein Database
2326173
Guide to Pharmacology
2617
UniProt Accession
HDAC3_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:14063
GenAtlas
HDAC4
GeneCards
HDAC4
GenBank Gene Database
AF132607
Guide to Pharmacology
2659
UniProt Accession
HDAC4_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:14068
GenAtlas
HDAC5
GeneCards
HDAC5
GenBank Gene Database
BK000028
Guide to Pharmacology
2660
UniProt Accession
HDAC5_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:14067
GenAtlas
HDAC7
GeneCards
HDAC7
GenBank Gene Database
BC020505
Guide to Pharmacology
2661
UniProt Accession
HDAC7_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:13315
GenAtlas
HDAC8
GeneCards
HDAC8
GenBank Gene Database
AF230097
GenBank Protein Database
8118721
Guide to Pharmacology
2619
UniProt Accession
HDAC8_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:14065
GenAtlas
HDAC9
GeneCards
HDAC9
GenBank Gene Database
AY032737
GenBank Protein Database
15590680
Guide to Pharmacology
2620
UniProt Accession
HDAC9_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:18128
GenAtlas
HDAC10
GeneCards
HDAC10
GenBank Gene Database
AL512711
Guide to Pharmacology
2614
UniProt Accession
HDA10_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:14064
GenAtlas
HDAC6
GeneCards
HDAC6
GenBank Gene Database
AF132609
GenBank Protein Database
4754911
Guide to Pharmacology
2618
UniProt Accession
HDAC6_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:4852
GenAtlas
HDAC1
GeneCards
HDAC1
GenBank Gene Database
U50079
GenBank Protein Database
1277084
Guide to Pharmacology
2658
UniProt Accession
HDAC1_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:2637
GenAtlas
CYP3A4
GeneCards
CYP3A4
GenBank Gene Database
M18907
Guide to Pharmacology
1337
UniProt Accession
CP3A4_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:2625
GenAtlas
CYP2D6
GeneCards
CYP2D6
GenBank Gene Database
M20403
GenBank Protein Database
181350
Guide to Pharmacology
1329
UniProt Accession
CP2D6_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:40
GenAtlas
ABCB1
GeneCards
ABCB1
GenBank Gene Database
M14758
GenBank Protein Database
307180
Guide to Pharmacology
768
UniProt Accession
MDR1_HUMAN
Patent information
2 active patents, 3 expired
Source: DrugBank · CC BY-NC 4.0. Patent data sourced from national patent offices. Expiry dates may not reflect extensions, regulatory exclusivity periods, or legal challenges.
DrugBank citations
If you use DrugBank data in your research, please cite the following publications: